Piramal unfazed even as Trump return may fuel uncertainty in its biggest market
Subscribe to enjoy similar stories. Piramal Pharma Ltd is confident that the company’s American facilities can help it navigate the volatility in its largest market US following Donald Trump’s comeback, according to chairperson Nandini Piramal. Trump’s second inning is likely to spell uncertainty for pharma companies, she told Mint, referring to his plan to impose import tariffs to make American industry stronger.
“I do think there will be an increase in volatility, but one of the benefits is that we do have manufacturing based in the states. For the customers that can pay the prices, we can manufacture for them. Overall, the Indian industry has lower prices for worldwide patients, which is a good thing." Nearly two-thirds of Piramal Pharma’s revenue comes from the developed markets, out of which the US comprises 35%.
The company has three US-based facilities: Riverview, Michighan for making high potency active pharmaceutical ingredients (APIs); Sellersville, Pennsylvania, which manufactures oral solids, creams, liquids and ointments; and Lexington, Kentucky for making sterile Injectables. The company also expects to be better placed in the US in the coming years as the Biosecure Act comes into play. The US House of Representatives passed the act in September, prohibiting American pharma players from doing business with certain Chinese drug companies starting 2032.
Read more on livemint.com
